Prescription medication · Lipoglycopeptide Antibiotic
dalbavancin
Also sold as Dalvance. Dalbavancin treats acute bacterial skin and skin structure infections (ABSSSI).
Data updated 2026-05-15
- 911
- FDA reportsRarely reported
- Rx
- Availability
dalbavancin (Dalvance) is a prescription Lipoglycopeptide Antibiotic. Dalbavancin treats acute bacterial skin and skin structure infections (ABSSSI).
Dalbavancin is an antibiotic medicine. It fights bacterial infections of the skin and tissues under the skin.
Verify with FDA → · CMS NADAC pricing →
What it does
Dalbavancin treats acute bacterial skin and skin structure infections (ABSSSI).
Common side effects
Nausea, Headache, Diarrhea
Key warnings
Serious allergic reactions and skin reactions have been reported.
The sections below are summarized in plain English from dalbavancin's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Dalbavancin is a lipoglycopeptide antibiotic. It works by stopping bacteria from growing. This helps your body fight off the infection.
Side Effects (from patient reports)
Based on 911 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for dalbavancin, by number of reports
- Rash
Rash
93 reports
- Back Pain
Back Pain
55 reports
- Pruritus
Pruritus
55 reports
- Dyspnoea
Dyspnoea
53 reports
- Nausea
Nausea
49 reports
- Hypersensitivity
Hypersensitivity
45 reports
- Erythema
Erythema
42 reports
- Vomiting
Vomiting
42 reports
- Urticaria 37
Urticaria
37 reports
- Chest Discomfort 28
Chest Discomfort
28 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for dalbavancin each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where dalbavancin sits
dalbavancin has more FDA adverse-event reports than 6% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is dalbavancin; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 911 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2014–2025.
Total Reports
911
Reports Mentioning Death
20
2.2% of reports — not proof of cause
Hospitalization Reports
207
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | RASH | 93 |
| 3 | BACK PAIN | 55 |
| 4 | PRURITUS | 55 |
| 5 | DYSPNOEA | 53 |
| 7 | NAUSEA | 49 |
| 8 | HYPERSENSITIVITY | 45 |
| 9 | ERYTHEMA | 42 |
| 10 | VOMITING | 42 |
| 11 | URTICARIA | 37 |
| 12 | CHEST DISCOMFORT | 28 |
| 13 | INFUSION RELATED REACTION | 28 |
| 14 | DIARRHOEA | 26 |
| 15 | PYREXIA | 25 |
| 16 | ANAPHYLACTIC REACTION | 24 |
| 17 | CHEST PAIN | 22 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Serious allergic reactions and skin reactions have been reported. Tell your doctor right away if you have any signs of an allergic reaction. Rapid IV infusion can cause flushing, rash, itching, and back pain. Slowing the infusion may help.
Common Questions
What if I am allergic to glycopeptide antibiotics?
Can dalbavancin cause diarrhea?
Will dalbavancin affect my liver?
Can children take dalbavancin?
What if my kidneys don't work well?
Are there any drug interactions?
How will I receive dalbavancin?
How long does the infusion take?
What if I experience flushing or itching during the infusion?
What kind of bacteria does dalbavancin treat?
What are the common side effects of dalbavancin?
What drug class is dalbavancin?
What pregnancy or breastfeeding source fields are listed for dalbavancin?
Related Medications in Lipoglycopeptide Antibiotic
Other drugs grouped near dalbavancin - same-class peers and common alternatives.
amikacin
Amikin
Amikacin is an antibiotic medicine.
Compare with dalbavancin →
amoxicillin
Amoxil
Amoxicillin and Clavulanate Potassium is a combination medicine used to fight bacterial infections.
Compare with dalbavancin →
amoxicillin/clavulanate
Augmentin
Augmentin is a combination of two medicines, amoxicillin and clavulanate.
Compare with dalbavancin →
ampicillin/sulbactam
Unasyn
Unasyn is a combination of two antibiotics that fights bacteria in your body.
Compare with dalbavancin →
azithromycin
Zithromax, Z-Pack
Azithromycin is an antibiotic that fights bacteria.
Compare with dalbavancin →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for dalbavancin: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 911.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 2.20%.
- eluxadoline Δ 0.00 pts · 2,870 reports · Mu-Opioid Receptor Agonist (IBS-D) 2.20%death share
- progesterone Δ 0.07 pts · 21,004 reports · Progestogen Hormone 2.27%death share
- canagliflozin Δ 0.10 pts · 29,554 reports · SGLT2 Inhibitor 2.29%death share
- liothyronine Δ 0.12 pts · 8,408 reports · Thyroid Hormone (T3) 2.32%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on dalbavancin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for dalbavancin
The FDA label for dalbavancin (sold under brand names such as Dalvance) classifies it as a prescription-only medication in the Lipoglycopeptide Antibiotic class. Dalbavancin treats acute bacterial skin and skin structure infections (ABSSSI). Official labeling lists 3 commonly reported side effects, including Nausea, Headache, Diarrhea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 911 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: October 6, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages